Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ARTV
stocks logo

ARTV

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast ARTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARTV is 16.50 USD with a low forecast of 10.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast ARTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARTV is 16.50 USD with a low forecast of 10.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.775
sliders
Low
10.00
Averages
16.50
High
23.00
Current: 3.775
sliders
Low
10.00
Averages
16.50
High
23.00
Wedbush
Outperform
maintain
$18 -> $23
2025-10-17
Reason
Wedbush
Price Target
$18 -> $23
2025-10-17
maintain
Outperform
Reason
Wedbush raised the firm's price target on Artiva Biotherapeutics to $23 from $18 and keeps an Outperform rating on the shares. The firm notes the company announced refractory rheumatoid arthritis as the lead indication for AlloNK and announced FDA Fast Track Designation, with pivotal development possible as early as 2026 pending regulatory discussions. Importantly, the development program will feature low-dose lymphodepletion to maximize B cell depletion while minimizing adverse impacts among this patient population.
H.C. Wainwright
Emily Bodnar
Buy
initiated
$12
2025-06-11
Reason
H.C. Wainwright
Emily Bodnar
Price Target
$12
2025-06-11
initiated
Buy
Reason
H.C. Wainwright analyst Emily Bodnar assumed coverage of Artiva Biotherapeutics with a Buy rating and $12 price target. The company's primary asset, AB-101, a nongenetically modified natural killer cell therapy being evaluated in various B-cell driven autoimmune diseases in combination with anti-CD20 monoclonal antibodies has potential to establish itself as a safe, efficacious, and outpatient-accessible treatment, the analyst tells investors in a research note. The firm sees significant share upside potential if initial safety and translational data in B-cell driven autoimmune diseases delivered by the end of 2025 and longer follow-up efficacy data in the first half of 2025 from the company's various Phase 1/2 studies are positive.
Needham
Gil Blum
Strong Buy
Reiterates
$23
2025-04-08
Reason
Needham
Gil Blum
Price Target
$23
2025-04-08
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$20
2025-03-26
Reason
HC Wainwright & Co.
Edward White
Price Target
$20
2025-03-26
Reiterates
Strong Buy
Reason
Wedbush
Martin Fan
Buy
Reiterates
$18
2025-03-25
Reason
Wedbush
Martin Fan
Price Target
$18
2025-03-25
Reiterates
Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$23
2025-03-25
Reason
Needham
Gil Blum
Price Target
$23
2025-03-25
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Artiva Biotherapeutics Inc (ARTV.O) is -1.12, compared to its 5-year average forward P/E of -1.93. For a more detailed relative valuation and DCF analysis to assess Artiva Biotherapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.93
Current PE
-1.12
Overvalued PE
-0.60
Undervalued PE
-3.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.55
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.23
Undervalued EV/EBITDA
-4.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1276.02
Current PS
0.00
Overvalued PS
2904.57
Undervalued PS
-352.53
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ARTV News & Events

Events Timeline

(ET)
2025-11-12
07:31:29
Artiva Biotherapeutics Reveals Safety and Translational Findings from AlloNK
select
2025-11-12
07:04:03
Artiva Biotherapeutics announces Q3 earnings per share of 88 cents, compared to a loss of 92 cents in the same period last year.
select
2025-05-13 (ET)
2025-05-13
17:04:15
Artiva Biotherapeutics announces new, long-term data for AlloNK combination
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
10-19Yahoo Finance
Artiva Biotherapeutics (ARTV) Soars 113.9% Following FDA Fast Track Designation for AlloNK in Refractory RA – Is the Bullish Outlook Still Valid?

  • FDA Fast Track Designation: Artiva Biotherapeutics' lead candidate AlloNK has received Fast Track Designation from the FDA for refractory rheumatoid arthritis, marking it as the first deep B-cell depleting therapy to gain this recognition, which could enhance treatment options for patients.

  • Investment Implications: The Fast Track designation may improve Artiva's investment narrative by attracting investor interest and positioning the company favorably in the autoimmune treatment pipeline, despite ongoing financial challenges and the need for successful clinical trials.

[object Object]
Preview
4.5
10-18TipRanks
Friday's Major Stock Market Highlights: Morning News Summary!

  • Final Trading Day: Investors are advised to stay informed as the final day of trading this week approaches, with significant stock market news to consider.

  • Stock Market Updates: Traders can find more detailed stock market stories and updates at TipRanks.

[object Object]
Preview
9.0
10-17TipRanks
What’s Behind the 105% Surge in Artiva Biotherapeutics Stock (ARTV) Today?

  • FDA Fast Track Designation: Artiva Biotherapeutics' stock rose significantly after the FDA granted Fast Track Designation for its AlloNK treatment for refractory rheumatoid arthritis, a condition that does not respond to standard therapies.

  • Future Plans and Market Response: The company plans to share patient safety data in November and expects to release clinical response data in 2026, while analysts maintain a Strong Buy rating with a potential price target indicating significant upside for the stock.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Artiva Biotherapeutics Inc (ARTV) stock price today?

The current price of ARTV is 3.775 USD — it has increased 5.45 % in the last trading day.

arrow icon

What is Artiva Biotherapeutics Inc (ARTV)'s business?

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

arrow icon

What is the price predicton of ARTV Stock?

Wall Street analysts forecast ARTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARTV is 16.50 USD with a low forecast of 10.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Artiva Biotherapeutics Inc (ARTV)'s revenue for the last quarter?

Artiva Biotherapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Artiva Biotherapeutics Inc (ARTV)'s earnings per share (EPS) for the last quarter?

Artiva Biotherapeutics Inc. EPS for the last quarter amounts to -0.88 USD, decreased -4.35 % YoY.

arrow icon

What changes have occurred in the market's expectations for Artiva Biotherapeutics Inc (ARTV)'s fundamentals?

The market is revising No Change the revenue expectations for Artiva Biotherapeutics, Inc. (ARTV) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 4.57%.
arrow icon

How many employees does Artiva Biotherapeutics Inc (ARTV). have?

Artiva Biotherapeutics Inc (ARTV) has 89 emplpoyees as of December 05 2025.

arrow icon

What is Artiva Biotherapeutics Inc (ARTV) market cap?

Today ARTV has the market capitalization of 81.98M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free